No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects

Documenti analoghi

• Early pembrolizumab clearance as prognostic biomarker for non‐response in patients with advanced non‐small cell lung cancer
  di: Fenna de Vries, et al.
  Pubblicazione: (2025)
• Population pharmacokinetics and optimized dosing of cefuroxime in critically ill patients
  di: Jaap W. A. Mouton, et al.
  Pubblicazione: (2025)
• Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non‐covalent BTK inhibitor, in healthy subjects: First‐in‐human phase I study
  di: Kyoko Miyamoto, et al.
  Pubblicazione: (2024)
• A case of hepatoid adenocarcinoma of the lung harboring KRAS G12C responded favorably to sotorasib
  di: Hironori Uruga, et al.
  Pubblicazione: (2024)
• Effect of fluconazole on the pharmacokinetics of ainuovirine in healthy adult subjects
  Pubblicazione: (2024)